Pharma Stocks Under Pressure as Trump Talks Tariffs...

Pharma stocks are likely to be in focus today, July 16, after former U.S. President Donald Trump hinted at new pharmaceutical import tariffs by the end of this month. This could directly affect Indian pharma companies, many of which rely heavily on exports to the U.S., especially in generic drug formulations. Trump said the U.S. would start with low tariffs, giving companies around a year to shift manufacturing to the U.S., and then raise the tariffs significantly—potentially up to 200%. His goal is to encourage onshore drug production, but this puts Indian manufacturers in a tight spot. Generic drugs already operate on thin margins, and if Indian companies can't shift manufacturing or hike prices, production may become unviable. Experts warn this could even lead to drug shortages in the U.S., as Indian firms are key global suppliers. Market Snapshot: • Nifty Pharma Index is down ~3.4% YTD (Year-To-Date) • Gained ~2.5% so far in July as markets hoped for relief • Sentiment now turns cautious post fresh tariff remarks The fear is that if the tariffs are imposed and Indian pharma companies are unable to absorb the cost or relocate production, profitability could take a major hit, and some may be forced to scale down exports altogether. For now, expect pharma stocks to react sharply as global investors re-evaluate the risk to earnings from the U.S. market—the largest buyer of Indian drugs.